about
Biatrial Cardiac Metastases in a Patient with Uterine Cervix Malignant MelanomaSevere pulmonary haemorrhage accompanying hepatorenal failure in fulminant leptospirosis.Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer.Leptin and breast cancer: an overview.Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial).An update on the multimodality of localized rectal cancer.Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes?A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study.The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.An atypical case of POEMS syndrome with IgG kappa M protein and end stage renal failure.Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection.Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases.The acute effect of tropisetron on ECG parameters in cancer patients.The relationship between nutritional status and handgrip strength in adult cancer patients: a cross-sectional study.Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study.Changes in lifestyle upon diagnosis of cancer or other chronic illnesses: A Turkish Oncology Group study.Factors related to truth-telling practice of physicians treating patients with cancer in TurkeyBrucellosis in febrile neutropeniaThe debate about maintenance is not over in small-cell lung cancerThe impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitorsSerum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancerDo high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group studyBenefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group StudyThe real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohortKras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group studyComparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational studyThe Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer
P50
Q35594512-F00FC9EF-DD74-478A-85B9-C46933D2F528Q36710304-7D86D263-47B7-4ADA-A8EF-2AEF1918CA6FQ37092749-88993C6F-1164-4EC6-9F03-8ADB10D4FBEDQ37923859-3F776C40-C188-4094-A4B4-3779AB75848BQ39022398-538C8D93-1316-46F4-8C1C-6D5B2837F484Q39033376-08968E39-1661-4CA5-8DED-359CC9C3EEC6Q39934360-53941D4C-8C63-4B31-BF13-0A88D34C8AD5Q40180945-A63E5948-79AF-40AE-BDEF-FC38B8F244B8Q43243835-8CD6FE74-4F2C-4477-BD99-090BD5F829F4Q43575627-919D02BF-A0B6-4499-92B7-21DE9040D087Q44514729-AEEA93E5-E1A6-4BDB-9044-CCD4CBE6C01DQ45723475-A9D7F194-BC86-4CE1-B9C9-EFAE850B4953Q46778908-4CA1BB3E-FBFA-4DCC-BC7E-FF15A9018F95Q50089473-A7C48609-443B-4748-95AD-1E85FF7284DEQ50181358-FB373C80-BE79-4E14-A92E-7357BEA08EA7Q51420501-43DCDB8A-42EF-4C4E-B221-50103715D900Q54177115-DA548338-696C-4A6D-AB65-47C4EC552EC3Q54192368-76033E43-F237-45BB-8AE9-1025B97C23ABQ54409187-6023C798-BBC8-477F-9B61-B9F9FE0CAE98Q79238171-DE38BA93-CFD8-48E0-879C-800FB2DBE8E3Q80206237-93B10053-6ABB-4435-AAB4-9783C1D85A31Q80224648-F1ABD960-7C29-4B72-895C-AC589CB44776Q81211447-42FACADE-7938-4DEB-BBCB-75D62F9FAB53Q83145570-FD73E0A9-4918-4241-A098-68D9FEBE520FQ84649730-EE5F1E0A-B4FF-4748-816D-A3FCC79A3FC4Q87929553-A02D890A-C86C-4621-9ADA-707E4A51D3C3Q89325917-9DE5D7F2-585C-44D3-94B5-3D06039CD447Q89733576-E77AA623-8731-4831-9862-9C5CA06E582DQ91454084-833A3B65-49FD-4D3D-AFBC-20E04CDB8B5FQ92958821-FE2ED95E-B2EA-4FBF-9CD2-B7284B9369E3Q95515983-1B16C23D-1E1C-41C9-AAC6-43EA9011D7FD
P50
description
researcher
@en
wetenschapper
@nl
name
Mehmet Artac
@en
Mehmet Artac
@nl
type
label
Mehmet Artac
@en
Mehmet Artac
@nl
prefLabel
Mehmet Artac
@en
Mehmet Artac
@nl
P106
P31
P496
0000-0003-2335-3354